Preparation for Restenosis Prevention
Abstract
The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water .gtoreq.0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.
Claims
exact text as granted — not AI-modified1 - 15 . (canceled)
16 . A catheter balloon comprising paclitaxel and a gel coated thereon.
17 . The catheter balloon of claim 16 wherein the paclitaxel and gel are mixed together in a preparation.
18 . The catheter balloon of claim 17 wherein the preparation further comprises a coagulation inhibitor.
19 . The catheter balloon of claim 17 wherein the preparation further comprises a platelet aggregation inhibitor.
20 . The catheter balloon of claim 17 wherein the preparation further comprises an enzyme inhibitor.
21 . The catheter balloon of claim 17 wherein the preparation further comprises a calcium chelator.
22 . The catheter balloon of claim 17 wherein the preparation further comprises an agent for enhancing artery/vein imaging.
23 . The catheter balloon of claim 22 wherein the agent for enhancing artery/vein imaging is an X-ray contrast medium.
24 . The catheter balloon of claim 17 wherein the preparation comprises a solubility promoter that does not form micelles.
25 . The catheter balloon of claim 17 wherein the preparation is present in an amount effective for restenosis prevention.
26 . The catheter balloon of claim 16 wherein the paclitaxel is present in an amount effective to irreversibly or reversibly bind to tissue at a minimum percentage of 10%.
27 . A method of treating vein or artery wall for preventing restensosis comprising local delivery of paclitaxel using the catheter balloon of claim 16 .Join the waitlist — get patent alerts
Track US2014227193A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.